BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020

RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its third quarter 2020 financial results before the open of the U.S. financial markets on Thursday, November 5, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

See the original post here:
BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020

Read more
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2020 Financial and Operational Results on November 6, 2020

BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Friday, November 6, 2020 at 8:30 a.m. ET to discuss operational and financial results for the third quarter ended September 30, 2020.

See more here:
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2020 Financial and Operational Results on November 6, 2020

Read more
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride…

New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020 New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020

Follow this link:
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride...

Read more
Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020

Orphazyme A/SCompany announcement                                                                                       No. 67/2020                                                                                                          Company Registration No. 32266355

More here:
Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020

Read more
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe

COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted Orphan Designation to TransCon PTH for the treatment of hypoparathyroidism (HP).

Read the original here:
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe

Read more
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated randomized Phase II clinical trial evaluating its lead product candidate eftilagimod alpha (“efti” or “IMP321”) in hospitalized patients with COVID-19. The necessary approvals from the Czech Republic’s State Institute for Drug Control (SUKL- competent authority) and ethics committee have now been obtained, enabling the recruitment of patients to commence immediately. Initial interim results are expected to be reported from early 2021.

Read the original here:
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

Read more
Assertio to Release Third Quarter 2020 Financial Results and Host Webcast on November 6, 2020

LAKE FOREST, Ill., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its third quarter 2020 financial results will be released on Friday, November 6, 2020. Following the announcement, Assertio’s management team will host a live webcast at 8:30 a.m. Eastern Time to review the Company’s financial and operating results, and provide a general business update.

Visit link:
Assertio to Release Third Quarter 2020 Financial Results and Host Webcast on November 6, 2020

Read more